CEREFOLIN NAC Rx
Generic Name and Formulations:
L-methylfolate calcium (Metafolin) 6mg, Algae-S powder 90.314mg, methylcobalamin 2mg, N-acetylcysteine 600mg; caplets.
Alfasigma USA, Inc.
Indications for CEREFOLIN NAC:
Clinical dietary management of mild cognitive impairment.
Use only under medical supervision. 1 caplet daily.
Avoid if renal stones occur. Do not administer to critically ill patients. Folic acid may mask Vit.B12 deficiency, including pernicious anemia. History of peptic ulcer. Chronic liver disease. Pre-term newborns. Nursing mothers: not recommended.
Concomitant nitrates: increased risk of headaches. Capecitabine toxicity increased with addition of leucovorin. May produce false-positive result in nitroprusside test for ketone bodies.
Allergic reactions, mild transient diarrhea, itching, transitory exanthema, feeling body swelling, nausea, vomiting, rash, flushing, epigastric pain, constipation, headache; rare: renal stones.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds